The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660

A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su...

Descripción completa

Detalles Bibliográficos
Autor principal: Orenstein, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868035/
https://www.ncbi.nlm.nih.gov/pubmed/36342653
http://dx.doi.org/10.1007/s40121-022-00714-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868035/
https://www.ncbi.nlm.nih.gov/pubmed/36342653
http://dx.doi.org/10.1007/s40121-022-00714-9

Ejemplares similares